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Abstract
This study investigates inequality and inequity in pharmaceutical utilization in
Ontario. First, I compare inequality and inequity in drug use between senior and non-senior
population in Ontario at each of three points in time. During this time period, all seniors in
Ontario have been universally covered by the publicly financed OBD program. This is not
the case for the non-senior population. Second, I examine the changes in inequality and
inequity for each population group at each of the three time points: 1990, 1996/97 and
2000/01. During this period, cost-sharing and other changes were introduced into the ODB,
which allows us to identify the influence on equity of changes on drug coverage policies.
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1. Introduction
Most developed countries regard equity in health care access as a crucial element of
health system performance. Canada has achieved universal, first-dollar coverage 1 for its
population for a comprehensive package of medically necessary physician and hospital
services. However, even under public and universal coverage, the patterns of equity in the
utilization of these services vary. For GP and hospital services, most studies (Eyles et al.
1995; Newbold et al. 1995; Van Doorslaer et al. 2002; Van Doorslaer et al. 2004; Van
Doorslaer et al. 1992) have found little or no evidence of inequity in access; variations in
utilization occur mainly according to need. For specialist services, however, a number of
studies (Alter et al. 1999; Van Doorslaer et al. 2002; Van Doorslaer et al. 2004) have found
evidence of inequity in access; variations in utilization reflect a strong influence of nonneed factors such as income and education.
Pharmaceutical insurance in out-of-hospital settings is neither universal nor
comprehensive within the public health insurance system in Canada. Currently, coverage
for prescription drugs in Canada is offered through a mixture of public and private
insurance plans. In 2000, 53% of Canadians were covered by public drug plans, 58% of
Canadians were covered by private drug plans, 13% of Canadians were covered by both
private and public drug plans, and 2% of Canadians didn’t have any form of drug coverage
(Fraser Group and Tristat Resources 2002).
The Canadian Institute for Health Information (2005a) estimates that expenditure on
prescribed drugs accounts for 82.5% of total drug expenditure in Canada in 2004. The nonprescribed drugs are mainly paid by individual out-of-pocket expenditure. For the
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prescribed drugs, the expenditures are shared by public drug insurance plans, private drug
insurance plans and individual out-of-pocket payment. In 2002, the public share of
spending on prescription drugs was 46.4%. The remaining proportions were paid by private
insurers (33.8%) and patients’ out-of-pocket money (19.8%).
Variation in drug coverage among the Canadian population may lead to inequity in
the access to needed medications. Although a few studies (Alan et al. 2002; Alan et al.
2005) have considered the distributional effects of public drug subsidies, no study has
evaluated overall equity in drug utilization. However, we need to investigate equity in drug
utilization because prescribed drug utilization has become a more and more important
component of health care services worldwide. In Canada, between 1975 and 2004, per
capita prescribed drug expenditure in Canada has risen from $119 to $562 2 ; and
expenditure on prescribed drugs as a proportion of total health expenditure has increased
from 6.3% to 13.8% (Canadian Institute for Health Information 2005b). Prescribed drug
expenditure has increased at a more rapid rate than any other health care expenditure.
Moreover, as drugs are used increasingly as the therapy of choice for many conditions, their
potential applications to improve health are expanding rapidly. Because equity in health
care access is the goal of most health care systems, when the importance of drug use among
health care services goes up, equity in drug utilization is increasingly important for overall
system performance.
This study investigates income-related equality and equity in pharmaceutical
utilization in Ontario and the influence of public drug insurance on this equality and equity.
The fundamental difference between inequity and inequality resides in the fact that inequity
represents inequality that is considered and qualified as unjust and avoidable. As a result,
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measuring inequality in pharmaceutical utilization represents the first step towards the
identification of inequity in pharmaceutical utilization. This is a two-dimensional study,
both cross-sectional and over time, and also across population groups. First, I compare
income-related equality and equity in drug use between the senior population and nonsenior population in Ontario at each of three points in time. All seniors in Ontario are
universally covered by the publicly financed Ontario Drug Benefit (ODB) program. This is
not the case for the non-senior population. Therefore, this difference in coverage provides
an opportunity to examine the impact of universal drug coverage on income-related
equality and equity in drug utilization. Second, I examine the changes in income-related
equality and equity for each population group at each of the three time points: 1990,
1996/97 and 2000/01. During this period, cost-sharing and other changes were introduced
into the ODB, which allow us to identify the influence on income-related equality and
equity of changes in drug coverage policies.
The analysis proceeds as follows. First, at each time point, I identify whether there
exists income-related inequality in observed drug utilization for each population group.
Inequality here refers to the degree to which the individuals in an income distribution have
shares of drug utilization that are unequal in quantity. Secondly, I measure the incomerelated inequity in drug use. The goal of most health care systems is equity rather than
equality. Equity here refers to horizontal equity, namely access to drugs by all people on
the basis of need. When the term “access” is used in most empirical studies, it is usually
defined as “receipt of treatment”. However, access to treatment and receipt of treatment
may not be the same thing. The former refers to the opportunities open to people, while the
latter is related to the realization of the opportunities. If an individual does not realize the
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opportunities at his or her own will, inequity in access may not be a problem. Since it is
difficult to find measures on opportunities open to people in the datasets, I follow most
empirical studies by measuring access as receipt of treatment in this analysis. Therefore, for
the system being equitable, people with equal need should utilize the same amount of drugs
regardless of their income or social economic status. Thirdly, I decompose the inequality
into its causes. The decomposition sheds light on the causes of inequity and can inform
efforts by policy makers to improve equity in drug utilization. Finally, I compare incomerelated inequality and inequity of drug use between population groups and time points.
In the next section, I briefly introduce drug coverage in Ontario. The third section
describes the data and methods that I am going to use. The fourth section presents my
results. In the last section, I will draw my conclusions.

2. Drug Coverage in Ontario
Coverage for prescription drugs in Ontario is offered through a mixture of public
and private insurance plans. In 2000, 62% of the residents of Ontario were covered by
various private drug plans (Fraser Group and Tristat Resources 2002). It is difficult to
obtain data on the percentage of Ontarians who were covered by private drug plans in 1990
and 1996/97. However, according to the Canadian Institute for Health Information (2005b),
the share of private insurers on prescription drug expenditure in Canada was constantly in
the range of 30.2% to 33.8% from 1988 to 2002. Therefore, we can believe that there are no
significant changes in the status of private drug coverage in our examining period.
Currently, there are three publicly financed provincial drug insurance programs in
operation, administered by the Drug Programs Branch of the Ministry of Health and Long-
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Term Care: the Ontario Drug Benefit (ODB), the Trillium Drug Program (TDP), and the
Special Drug Program (SDP).
The target populations of the Ontario Drug Benefit (ODB) program are seniors,
residents of long-term care facilities and homes for special service care, and social
assistance recipients. All seniors were universally and fully covered (with no co-payments
required) by this program from August 1975 to July 14, 1996. From July 15, 1996, single
seniors who have an annual income of $16,018 or more, and seniors in couples with a
combined annual income of $24,175 or more pay a $100 annual deductible per senior. After
paying the deductible, they then pay up to $6.11 toward the dispensing fee for each
prescription. All the other ODB eligible people may be asked to pay up to $2 for each
prescription.
The Trillium Drug Program (TDP) is available to all residents of Ontario with valid
Ontario Health Insurance (OHIP) who are not eligible for the ODB program. Individuals or
families can apply to the Trillium Drug Program if private insurance does not cover 100%
of their prescription drug costs. The program has a deductible that is based on income and
family size. The deductible is roughly 4% of total household income. The TDP is provided
as a last resort for those have a high level of out-of-pocket drug expenditure. It provides a
protective cap for Ontario residents on drug expenses. The TDP was established in April
1995. After its establishment, the number of TDP applications has grown rapidly over time.
From 1996 to 2001, the number of TDP applications increased from 18,172 to 59,599
(Ontario Ministry of Health and Long Term Care 2005).
The Special Drugs Program (SDP) covers the full cost of certain out-patient drugs
used in the treatment of specific conditions. For example the program covers many drugs
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for the treatment of cystic fibrosis. To qualify, an individual must have one of the diseases
or conditions covered and meet established criteria. Under the program there are no
deductibles or co-payments. Eligible people do not have to pay for these treatments. The
total public SDP cost increased from $82.6 million in 1996/97 to $107.3 million in
2000/01 3 (Ontario Ministry of Health and Long Term Care 2005).
At the first time point (1990) of my study, all seniors in Ontario were universally
and fully covered by the ODB program. Around 60% of non-seniors were protected by
various private drug insurances, and a small proportion of non-seniors who received social
assistance were also covered by the ODB. 4 At the last two time points of my study,
1996/97 and 2000/01, all seniors in Ontario were still universally covered by the ODB, but
they had to pay a deductible and some co-payments; for the non-seniors, there were two
new public financed drug insurance plans: TDP and SDP.
Difference on drug insurance coverage between seniors and non-seniors and the
over time policy changes may have the following influences on equality and equity in drug
utilization:
•

Equality and equity in drug utilization among seniors may be more pro-poor than
that among non-seniors.

•

The imposition of deductibles and co-payments for seniors in the mid of 1990s
might have a negative influence (pro-rich) on equality and equity in drug utilization.

•

The implementation of TDP and SDP may have a positive influence (pro-poor) on
equality and equity in drug utilization among non-seniors.

In the following analysis, I will examine the above hypotheses.
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3. Data, Variables and Methods
To analyze equality and equity in drug utilization, we need individual level
information on drug use, income, and other variables that may affect drug use, e.g., gender,
age, health status, recent illness and injury, education, immigration status, and additional
medical insurance information.

3.1 Data
The data for the three time points in this study come from 1990 Ontario Health
Survey (OHS), the public use file of 1996/97 National Population Health Survey (NPHS)
and the master file of 2000/01 Canadian Community Health Survey (CCHS).

OHS 1990
The 1990 Ontario Health Survey is a comprehensive health survey of the population
of Ontario, sampling all 42 public health units that existed at the time. Certain groups such
as the homeless, aboriginal people on reserves, and those living in institutions were
excluded. The survey was conducted by face-to-face interview from January 1990 to
November 1990 (excluding July).
The OHS asked each subject the following question regarding drug utilization:
“How many different numbers of prescription drugs have you taken in the last 4 weeks?”
Responses to this question form the basis for the measure of drug utilization in this analysis.
The OHS also contains measures of health status, socioeconomic status, household and
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demographic information, income, medical insurance, etc., which are necessary for this
analysis.
The total sample size for the OHS 1990 is 77,663. To make the analyses comparable
over time, the observations between age 1 and age 11 are excluded. The NPHS 1996/97 and
CCHS 2000/01 only contain information on drug utilization for people aged 12 and older.
The sample size for the non-senior population between age 12 and 64 is 53,820; the sample
size for the senior population aged 65 or over is 8,769.

NPHS 1996/97
The NPHS 1996/97 is the second cycle of the National Population Health Survey.
The National Population Health Survey (NPHS) is designed to collect information related
to the health of the Canadian population. It is composed of three component parts: the
survey of households; the survey of institutions and the survey of the North.
The household component includes household residents in all provinces, with the
principal exclusion of populations on Indian Reserves, Canadian Forces Bases and some
remote areas in Quebec and Ontario. This analysis employs the public use file of the
Ontario section from the household survey of the NPHS 1996/97. The household survey of
the NPHS contains two separate data files: a general micro-data file and a health micro-data
file. In each household, some limited information was collected from all household
members (general micro-data file); one person in each household was randomly selected for
a more in-depth interview (health micro-data file). The health micro-data file contains
information about drug utilization for people aged 12 and over. Therefore, my analysis is
based on the health micro-data file.
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The NPHS asked each subject 21 questions as whether he or she has taken a
particular kind of drug in the past month. A derived variable on “number of different drugs
taken in the past month” can be constructed based on those questions, and is the
measurement of drug utilization in this analysis. The NPHS also contains measures on
health status, socioeconomic status, household and demographic information, income,
medical insurance, etc., which are necessary for this analysis.
For the NPHS 1996/97 cycle, the Ontario provincial government provided extra
funds so that a larger sample of dwellings could be selected. The purpose of this buy-in was
to obtain sufficient sample size to provide reliable cross sectional estimates at subprovincial levels. Therefore, the Ontario part of the NPHS 1996/97 is also referred as OHS
1996/97. The total sample size for the Ontario health micro-data file in the NPHS 1996/97
cycle is 39,010. The sample size is 7,102 for the senior population, 31,908 for the nonsenior population.
For Ontario, data collection ran from October 1996 to August 1997, completely
after the reform of provincial drug plans in July 1996. Before July 15 1996, Ontario
provided first dollar coverage without any co-payment to its senior citizens. After that,
income and household size based deductible and dispensing fee were imposed. Similarly, a
$2 dispensing fee was introduced after July 15 1996 for the non-senior social assistance
recipients eligible for the provincial drug plan.

CCHS 2000-2001
The CCHS 2000/01 is the first cycle of the Canadian Community Health Survey, a
large sample, general population health survey. Information was collected between
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September 2000 and November 2001, for 136 health regions, covering all provinces and
territories. The CCHS (Cycle 1.1) collects responses from persons aged 12 or older, living
in private occupied dwellings. Individuals living on Indian Reserves and on Crown Lands,
institutional residents, full-time members of the Canadian Armed Forces, and residents of
certain remote regions are excluded.
The CCHS 2000/01 asked each subject 21 questions as to whether this individual
has taken a particular kind of drug in the past month. The questions are the same as in the
NPHS 1996/97. A derived variable on “number of different drugs taken in the past month”
can be constructed based on those questions, and is the measurement of drug utilization in
this analysis. One limitation is that the questions on drug use are optional in the CCHS
2000/01. Only regions with a need for data or interest in this topic selected it in the CCHS.
100% of the respondents in only 29 public health regions (out of 37) answered those
questions. The other 8 public health regions did not select this topic. 5 Therefore, the
observations in those 8 public health regions are excluded from this analysis. The number
of excluded observations is 20.7% of total observations, but it only represents 16.1% of
Ontario population. The comparison on descriptive statistics of some key characteristics
related to health care utilization between the included observations and excluded
observations is presented in Table 1. The two sets of numbers are very close, which
suggests no bias in terms of observed characteristics. In addition, individual respondents
played no role in the decision of whether or not to answer these questions, so there is no
individual-level selection process at work.

Hence, although the missing data are

unfortunate, little reason to believe it introduced serious selection bias. The CCHS 2000/01
also contains measures of health status, socioeconomic status, household and demographic
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information, income, etc. A further problem is that the information on additional medical
insurance is not collected in CCHS 2000/01.
The total sample size for the analysis based on the CCHS is 31,133. The sample size
for the senior population is 25,108, and for the non-senior population is 6,025.

3.2. Variables
In this analysis, I adopt the methods developed by the ECUITY group in recent
years (Van Doorslaer et al. 2002; Van Doorslaer et al. 2004; Van Doorslaer et al. 2000;
Van Doorslaer et al. 1992; Wagstaff and Van Doorslaer 2000a).This method has been
applied to many countries internationally, and to EU countries in particular on the issues of
equity in health care utilization. It has been applied at the national level in Canada with
respect to hospital and MD services. However, it has never been applied to equity in drug
utilization anywhere. The approach involves four basic steps at each time point for each
population group:
1) Calculate the concentration index (CI) to measure the inequality in observed
drug use.
2) Use a two-part model to indirectly need-standardize the drug use.
3) Calculate the horizontal inequity index (HI) to measure the inequity in drug
use.
4) Decompose the inequality into its causes.
The details of the method are discussed in the next sub-section. The variables used in the
two-part model are discussed below.
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Dependent Variable
The 1990 OHS asks each subject “How many different numbers of prescription
drugs have you taken in the last 4 weeks?”; NPHS health micro-data file and CCHS contain
21 identical questions about whether the respondent has taken a particular kind of drug in
the past month. The information is used to create the two dependent variables. The first is a
dichotomous variable indicating whether a person consumed at least one drug in the last
month. The second is the number of drugs used conditional on positive use.
There are two limitations to these measures of utilization. First, the number of
different drugs taken in the past month is a crude measurement of drug utilization. It is
related only to the crude measurement of quantity rather than the quality of drug use. If data
allowed, a more accurate measurement of drug utilization would give better estimation and
understanding of this issue. This is a very common issue in most existing studies on the
issue of equity in health care utilization. The commonly used dependent variables are
number of physician visits, number of dentist visits, and number of nights of hospital stay,
etc. Secondly, utilization in the NPHS and CCHS data include both prescribed and nonprescribed drugs, while the OHS includes only prescribed drugs. This may lead to
inconsistency of the results.

Independent Variables
Table 2 lists the independent variables included in the two-part model and briefly
describes the rationale for their inclusion. The independent variables can be categorized
into three groups: demographic variables, health status variables and social-economic
variables. The demographic variables include indicators of age, sex and immigrant status.
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Usually, there are strong relations between health care utilization and age and sex. Many
studies (e.g., Deri 2005) have found lower rates of health care utilization among immigrants,
therefore, an immigrant variable is included in the model. The health status variables
include self-assessed health status, number of chronic conditions and illness and injury in
the past two weeks. The social-economic variables include income per household member,
education level, working status, and additional medical insurance. Income per household
member is a critical variable in this analysis; it is created as follows. The OHS 1990 and
NPHS 1996/97 contain categorical information on total household income (0-$5000,
$5000-$9999, $10000-$14999, $15000-$19999, $20000-24999, $25000-$29999, $30000$39999, $40000-$49999, $50000-$59999, $60000-$79999, $80000+). The CCHS 2000/01
contains information on best estimate of total household income. All the datasets also
contain information on number of individuals in the household. Income per household is
defined as the mid point of the total household income in each category divided by the
number of household members in that household. Several variables may capture multiple
influences on drug utilization, such as education and working status, which are also
discussed in Table 2. The main purpose of the regression model is prediction rather than the
estimation of a causal relationship. Therefore, it is not a structural model.
The descriptive statistics of the variables are presented in Table 3 and Table 4. The
means of most independent variables are relatively constant over time; one exception is the
income per household member variable, which increased over time. For the non-seniors,
there are significant increases of the two dependent variables. The average number of drugs
used increased from 1.023 to 1.836, and the probability of drug use increased from 0.53 to
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0.805 from 1990 to 2000/01. For the senior population, the number of drugs used and the
probability of drug use increased slightly over time.

3.3. Method
Step 1- Concentration Index for Observed Drug Utilization
The concentration index quantifies the degree of inequality in a specific health
variable – in this case number of drugs consumed – across the income distribution. It is
defined with the reference to the concentration curve. The concentration curve graphs on
the x-axis the cumulative percentage of the population ranked by income and on the y-axis
the cumulative percentage of drug consumption.
If there is no income-related inequality, the concentration curve is the 450 line. If
drug consumption is more concentrated among the poor, the concentration curve lies above
the line of equality. If drug consumption is more concentrated among the rich, the
concentration curve lies below the line of equality. The concentration index is defined as
twice the area between the concentration curve and the line of equality (the 450 line). If the
concentration curve is above the 450 line, indicating that drug consumption is more
concentrated among the poor, the concentration index takes on a negative value. If the
concentration curve is below the 450 line, indicating that drug consumption is more
concentrated among the rich, the concentration index takes on a positive value. The
concentration index ranges from -1 to 1, -1 means that the poorest person gets all the drugs
consumed while 1 means that the richest person gets all the drugs consumed, and 0 means
that drug consumption is the same for every income level.

17

The concentration index is calculated by the following formula:
C=

2 n
∑ yi Ri − 1
nμ i =1

(1)

where yi is the drug consumption for individual i, Ri is the rank of income for that
individual, μ is the mean of drug consumption, and n is the number of individuals. Both
the concentration index and its variance can easily be computed using conventional
statistical software packages. With the standard error, we can test the statistical significance
of the concentration index and calculate its confidence interval.
The concentration index simply measures whether utilization is equal across the
income groups. The goal of a health care system is equity rather than equality. To assess
equity, we must assess the extent to which utilization is driven by need.

Step 2-Indirect Need-standardization of Drug Utilization
At the second step, I use a two-part model to indirectly need-standardize the drug
utilization. The goal of a health care system is equity rather than equality. A key principle
of equity for health care systems is allocation according to need. Under this principle,
horizontal equity requires that persons in equal need of treatment should receive the same
amount of treatment. Because the concentration index measures only the income-related
inequality in observed drug utilization, an analysis of equity in drug utilization requires that
we adjust for underlying need.
To adjust for need, I use the indirect need-standardization approach proposed by
Wagstaff and Van Doorsaler (2000). The measure of drug utilization used in this analysis is
the number of drugs used in the past month. The need-adjusted drug utilization can be
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predicted by a two-part model. Jones (2000) provides an overview of the econometric
methods that have been applied to this kind of count data. For the health data, it is common
to have a large proportion of zero observation, and “overdispersion”. Overdispersion means
that the variance of the distribution exceeds the mean. The two-part model accommodates
the high proportion of zeros. Under the two-part model in this situation, the first part is a
logit regression, and the second part is a Negative binomial regression, which deals with the
“overdispersion”. The dependent variable in the first part of the two-part model is a
dichotomous variable indicating whether a person consumed at least one drug in the last
month. The dependent variable in the second part of the two-part model is the number of
drugs used conditional on positive use.

With the two-part model, not only we could

measure the equity in the number of drugs used, but also we could measure the equity in the
probability of drug use. Moreover, several studies (Grootendorst 1995; Jones 2000; Van
Doorslaer et al. 2000) show that the two-part model is the best choice when the dependent
variable is a quantitative measure of health care utilization. Therefore, I adopt the two-part
model approach with appropriate modelling of the count data.
To measure equity, we need to create a measure in which utilization does not reflect
the influence of non-need factors; it reflects what utilization would be like if only needs
drove utilization. Therefore, the need-standardization requires that each variable be
classified as need-related or non-need-related. In this analysis, the following variables are
classified as need factors: self-assessed health status, age, number of chronic diseases and
illness/injury in the past two weeks; and the other variables are classified as non-need
factors: income, education level, immigrant status, additional insurance status, working
status. There is no unanimous agreement about what factors should be considered as need
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factors. Some researchers argue that some factors, such as education and working status,
should also be considered as need factors. In this case, I simply take the demographic and
morbidity factors as need factors, because these are much less controversial and are most
commonly defined as need factors in the equity studies of health care utilization.
After the estimation of each part, I fix the non-need factors at the sample means,
and then predict the need-standardized probability and need-standardized number of drugs
used conditional on positive use based on the need factors. By doing so, we assume the
population average relationship between need and treatment as the norm of equity. The
need-standardized expected total number of drug use is equal to the product of needstandardized probability and need-standardized conditional number.

Step 3-Horizontal Inequity Index
In the third step, I calculate the horizontal inequity index (HI) for the probability of
any drug use, conditional number of drugs used and total number of drugs used.
The horizontal inequity index is equivalent to the concentration index for y IS (Van
Doorslaer et al. 2000), where
∧

yiIS = yi − yi + y m

(2)
∧

where yi is the measure of actual drug utilization in the past month, yi is the need-adjusted
measure of drug utilization, and y m is the sample mean of the measure of drug utilization
in the past month.
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Step 4-Decomposition of Inequality
At the last step, I decompose the inequality in observed utilization into its causes. I
adopt the decomposition method proposed in Wagstaff et al. (2003). In order to use this
method, the number of drugs used has to be expressed by a linear equation of a set of
variables that determine drug utilization. In other words, the decomposition has to be based
on an OLS regression. Van Doorsaler et al. (2004) argue that in most cases, the
concentration index based on OLS predicted values is close to the true concentration index,
even if the dependent variable is a count measure. In my case, the concentration index
based on OLS predicted values is also close to the true concentration index. Therefore, I
follow the OLS approach. However, because of the nature of count data, the OLS based
decomposition of inequality is an approximation only.
In an OLS regression, the number of drugs used can be expressed as

yi = α + ∑ β k xki + ε i

(3)

k

where xk is a set of k determinants of y. The concentration index is

C=

2 n
∑ yi Ri − 1
nμ i =1

(4)

Substitute equation (3) into the above equation, it can be rearranged as

C = ∑(
k

Where

β k xk
GCε
)Ck +
μ
μ

(5)

β k xk
is the elasticity of drug use with respect to determinant k; Ck is the CI for
μ

variable k, and

GCε

μ

is an error term. The estimated inequality in drug use can be
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expressed as a weighted sum of the inequality in each of its determinants; the weights are
the drug use elasticities of the determinants. Based on the OLS regression, I decompose the
concentration index for each population group.

4. Results
Step 1: Concentration indices for observed drug use
Figure 1 and Figure 2 present the average number of drugs used and the average
number of drugs used for those who have consumed drugs by income quartile. The bar
graphs can give us a more intuitive impression on the inequality in drug use before I report
the concentration indices. Generally speaking, people in the lower income quartiles use
more drugs than people in the higher income quartiles. 6 Seniors use more drugs than nonseniors. And there is a trend of increase in drug utilization over time.
The concentration indices measuring the income-related inequality on observed
drug use are reported in Table 5. The distribution is pro-poor for the senior population at all
three time points, although not significantly different from zero in 1996/97. For the nonsenior population, the distribution is pro-poor in 1990 and pro-rich in 1996/97 and 2000/01.
At all time points, the concentration indices of the senior population are more negative or,
when positive, smaller (more pro-poor) than those for the non-senior population. From
1990 to 1996/97, there is an increase of the concentration index for both the senior and nonsenior population. The distribution is less pro-poor over time. This change may result from
the imposition of deductibles and co-payments of ODB for seniors and from a rapid
increase of drug utilization for non-seniors. During this period, for the non-senior
population, the average number of drugs used increased from 1.02 to 1.66, and the
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probability of drug use increased from 0.53 to 0.78. This increase reflects the changes in
health technology, whereby more conditions are being treated outside hospital settings. The
increased drug utilization might be unbalanced in favour of the rich.

From 1996/97 to

2000/01, the concentration index for the senior population slightly decreases (more propoor), while there is no significant change for the non-senior population. During this period,
there is no drug policy change for seniors, and the introduction of the Trillium Drug
Program and the Special Drug Program may mitigate the worsening of the income-related
inequality among the non-senior population. From 1996 to 2001, the number of TDP
applications increased from 18,172 to 59,599, and the total SDP cost increased from $82.6
million to $107.3 million. The aims of these two programs are to help those most in need
and who have greatest financial constraints. Given the income-related inequality in drug
utilization is relatively small, the TDP and SDP may have significant influence on the
distribution of drug utilization across income groups.

Step 2-Indirect Need-standardization of Drug Utilization
The goal of most health care systems is equity rather than equality. In order to
measure horizontal inequity, observed drug utilization must be indirectly need-standardized,
after which we can compute the horizontal inequity index.
The first part of the two-part model is a logit model on the probability of drug use.
The second part of the two-part model is a negative binomial model conditional on positive
drug use. In view of space considerations, the results of the two-part model are not reported
here. 7 The general patterns are very similar for both parts. Generally speaking, at all three
time points, for both the senior and non-senior population, there is a strong relationship
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between drug utilization and need factors (number of chronic diseases, illness/injury in the
past two weeks, self-assessed health status, sex, age). Drug use is increasing in the number
of chronic diseases and worse self-assessed health status. The link between drug use and
non-need factors (education, immigration status, additional drug insurance, working status
and income) is much weaker. However, compared to the senior population, the link
between drug use and non-need factors is more salient for non-seniors. The role of
education, income, and immigrant in drug use are less significant for seniors. For both
seniors and non-seniors, at the later two time points, the magnitude of the link between
drug use and need factors is weaker than that in 1990, and the link between drug use and
non-need factors is stronger.
After the estimation, I fix the non-need factors at the sample means, and then
predict the need-standardized probability of drug use, number of drugs used conditional on
positive use, and total number of drugs used based on the need factors.

Step 3-Horizontal Inequity Index
In the third step, I calculate the horizontal inequity index (HI) for the probability of
drug use, drugs used conditional on positive use, and total number of drugs used. The
results are presented in Table 6.
There are no evidences of inequity in most aspects of drug use for both seniors and
non-seniors in 1990. The only exception is that the probability of drug use for non-seniors
is distributed slightly pro-rich. However, this pro-rich distribution for the probability of
drug use is offset by the pro-poor distribution for drugs used conditional on positive use;
therefore, there is no measured income-related inequity in the total number of drugs used
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even for non-seniors in 1990. There is evidence of income-related inequity for almost all
the aspects of drug use for both seniors and non-seniors in 1996/97 and 2000/01. However,
there are no significant differences in the level of inequity between the later two time points.
The worsening of equity may result partially from the same reasons that lead to the
worsening of inequality. I will discuss this in more details at next step.
At all the three time points, on all aspects of drug use, the equity performance for
seniors is better than that of non-seniors. The HI indices for seniors are more negative or,
when positive, smaller (more pro-poor) than that for non-seniors. Universal drug coverage
for the senior population might play an important role in drug utilization.

Step 4-Decomposition of inequality
At each time point, for each population group, I decompose the unadjusted
inequality (the concentration index) into the separate contributions of the various
determinants to the total inequality. The summarization of decomposition results are
presented in Table 7 and Figure 3.
At all three time points, the overall concentration indices for senior population are
more negative or smaller than that for non-senior population. There is a more pro-poor
distribution in drug use among seniors. The decompositions show that the most important
source of the more pro-poor distribution among seniors is that more seniors suffer from
poor health, and poor health among the seniors is concentrated among the poor. Compared
to non-seniors, the need factors, such as higher number of chronic conditions, worse selfassessed health statuses, and illness/injury in the past two weeks, are more concentrated
among the poor. Therefore, the concentration indices of these factors for seniors are more
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negative. Moreover, there is positive relationship between drug use and the need factors.
Therefore, for seniors, the need factors make larger negative contributions to the total CI’s.
Among non-seniors, people with relatively higher age usually have worse health status and
higher income; therefore, the need factors are less concentrated among the poor, and thus
make less negative contributions to the total CI’s. Part of the gap in the CI’s between
seniors and non-seniors results from the variables of education, immigration status and
additional drug insurance. Higher education levels and having additional medical insurance
are concentrated more among the rich in both the senior and non-senior population. At the
same time, the positive relationships between drug use and these two variables for nonseniors are stronger than those for seniors. Therefore, these two variables make positive
contributions to the gap of inequality in drug use between seniors and non-seniors.
Immigrants use fewer health care services presumably because of language barriers and
lack of information about the Canadian health care system, or some other cultural reasons.
However, immigration status has a different influence on drug use between senior and nonsenior populations. Generally speaking, the negative relationship between immigration
status and drug utilization is more significant for non-seniors. Moreover, for both seniors
and non-seniors, immigrants on average have less income, which implies the concentration
indices for immigration status are negative. Therefore, immigration status makes a positive
contribution to the gap of inequality in drug use between seniors and non-seniors. Generally
speaking, without universal coverage, the drug utilization of non-seniors is more influenced
by non-need factors.
For both seniors and non-seniors, the most important source for the worsening of
inequality in drug use over time comes from the income variable. In 1990, there is a
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negative but statistically insignificant relationship between drug use and income. In
1996/97 and 2000/01, the relationships between drug use and income become positive and
statistically significant, and leads to an increase of both inequality and inequity in drug use.
This change might be related to the introduction of deductibles and co-payments of ODB
for seniors, and the rapid increase in drug utilization for non-seniors during that period.
However, because we define equity in drug use in this study as drug use according
to need, and poor seniors are more in need, therefore, the gap of inequity in drug use (HI) 8
between seniors and non-seniors is not as large as the gap of inequality in drug use (CI)
between seniors and non-seniors. The horizontal inequity index measures only the
inequality in drug use that results from non-need factors. The gap in the HI’s between
seniors and non-seniors is smaller than the gap in the CI’s.

5. Conclusion
This study analyzes the equality and equity in pharmaceutical utilization in Ontario,
an issue which has not previously been examined. In 1990, I find no evidence for pro-rich
inequality and inequity in drug utilization in Ontario for both senior and non-senior
populations. In 1996/97 and 2000/01, I find evidence for pro-rich inequality and inequity
for both population groups. At all three time points, the equality and equity performance in
drug utilization for the senior population dominates that of the non-senior population.
Universal drug coverage for the senior population might play a role in drug utilization.
From 1990 to 1996/97, there is a worsening in equality and equity performance for both
senior and non-senior populations, so that the distribution is less pro-poor over time. This
result might be partly related to the introduction of deductibles and co-payments for ODB
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for seniors and to the rapid increase of drug utilization during this period. From 1996/97 to
2000/01, the equality and equity performance for the senior population slightly decreased,
while there is no significant change for the non-senior population. The introduction of the
Trillium Drug Program and the Special Drug Program might mitigate the worsening of
income-related inequality and inequity among the non-senior population.
Decomposing the inequality into its causes reveals that poor seniors are more in
need of drug utilization than poor non-seniors, resulting in more pro-poor distribution of
drug utilization among seniors. The gap in equity performance between seniors and nonseniors is not as large as the gap in equality. The gap in equity performance between
seniors and non-seniors mainly results from the variables of education, immigration status
and additional drug insurance. Without universal coverage, these variables have greater
influence on drug utilization among non-seniors. For both seniors and non-seniors, the most
important cause of worsening equality and equity in drug use over time comes from the
income variable. This relationship between drug use and income becomes positive and
statistically significant over time.
These findings may be confounded by other system changes in the health care
sector during the study period. The major changes in the physician sector during 1990’s
would be the introduction and then removal of global physician expenditure caps. The other
major change would have been hospital restructuring in the late 1990’s. These system
changes may have influence on drug utilization. However, the impact from these changes
on the distribution of drug use should be much smaller than the impact on the overall drug
use.
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The most important policy implication to be derived from this study is that equity
performance in drug utilization is closely related to drug coverage policy. Expansion of
special public drug programs for people highly in need (for example, TDP and SDP), or
introducing programs for under-utilizing groups such as immigrants (for example,
programs to reduce language barriers) would improve equity in drug utilization.

Notes
I would like to thank Jerry Hurley, Tom Crossley, and an anonymous referee for helpful
comments. I also acknowledge the data support by Statistics Canada RDC at McMaster and
UWO.
1

First-dollar coverage refers to the health insurance plan without deductibles and co-

payments.
2

Values are converted in 2004 constant dollars.

3

Approximately 1.9% out of total drug expenditure in Ontario in 1996 and 1.7% in 2000.

4

It’s difficult to estimate the size of this group of people. According to Social Development

Canada (2005), in each year, 5% to 8% Ontarians received social assistance from 1999 to
2004. Among them, a significant proportion is children and seniors.
5

The eight excluded PHU’s are: Haliburton-Kawartha-Pine Ridge PHU, Hastings and

Prince Edward PHU, Brant PHU, Renfrew PHU, KFLA PHU, Ottawa-Carleton PHU,
Eastern Ontario PHU and Leeds-Grenville-Lanark PHU.

29

6

These seemingly “pro-poor” results are not yet adjusted for need and if the poor have

greater need, it may nonetheless be the case that the utilization of drugs is not equitable
with the poor possibly receiving less drugs than would be equitable based on need.
7

Results of step 2 are available upon request.

8

By definition, HI index is equal to the sum of contributions of non-need factors to the

total inequality.
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Tables
Table-1, Comparison of descriptive statistics between included and excluded
PHU's, CCHS 2000/01
Excluded PHU's Included PHU's
Std.
Std.
Mean
dev. Mean
dev.
Household income
60339 31452 61510 31166
Education- less than high school
0.270 0.444 0.269 0.444
Education- high school
0.197 0.397 0.209 0.406
Education- some post secondary
0.073 0.260 0.077 0.267
Education- post secondary graduation
0.451 0.498 0.438 0.496
Female
0.511 0.500 0.509 0.500
Age 12-14
0.048 0.213 0.044 0.205
Age 15-19
0.080 0.271 0.081 0.273
Age 20-24
0.077 0.266 0.081 0.273
Age 25-29
0.076 0.264 0.080 0.271
Age 30-34
0.077 0.267 0.088 0.283
Age 35-39
0.100 0.300 0.110 0.313
Age 40-44
0.104 0.305 0.103 0.303
Age 45-49
0.084 0.278 0.093 0.290
Age 50-54
0.089 0.285 0.077 0.267
Age 55-59
0.065 0.247 0.057 0.233
Age 60-64
0.047 0.213 0.046 0.210
Age 65-69
0.051 0.220 0.043 0.204
Age 70-74
0.039 0.194 0.039 0.195
Age 75-79
0.033 0.177 0.030 0.170
Age 80+
0.030 0.171 0.027 0.163
Self-assessed health- excellent
0.254 0.435 0.267 0.442
Self-assessed health-very good
0.373 0.484 0.365 0.481
Self-assessed health-good
0.250 0.433 0.246 0.431
Self-assessed health-fair
0.088 0.283 0.086 0.280
Self-assessed health-poor
0.034 0.181 0.036 0.186
Number of family doctor visits in past
3.407 4.778 3.402 4.602
year
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Table-2, Independent Variables: Description and Rationale for Inclusion
Variable

Description and Rationale

Need
Status

Demographics
Age
Age of the respondent at the time of interview. Age is defined by a series of 15 categorical variables.
The reference category is age 12-14. Age is associated with chronic health decline and need for drugs.
The use of age-specific dummy variable allows maximum flexibility in the age-utilization relationship.
Female
Male and female have different attitudes and needs for health care services. Sex is indicated by a
dummy variable, at which female is 1 and male is 0.
Immigrant
Indicator of whether the respondent is an immigrant. Immigrant is defined in all the three surveys as
not born in Canada. Immigrants may experience barriers to drug utilization because of language
barriers and lack of information about the Canadian health care system.
Health Status
SelfRespondent’s self-assessed health status, defined by a series of 5 categorical variables (Excellent,
assessed
Very Good, Good, Fair, And Poor). The reference category is excellent. Self-assessed health status is
health
a well-validated general health measure, which is strongly associated with drug utilization.
status
Illness/injury Indicator of whether the respondent has illness or injury (self-reported) in the past two weeks.
Illness/injury refers to conditions that related to stay in the bed or cutting down on activities, which may
positively relate to drug utilization.
Chronic
Respondent’s self-reported number of chronic conditions. Chronic conditions are strongly associated
conditions
with drug utilization.
Socio-economic Status
Income
Income per household member, in thousands. Income may be positively related to the drug utilization.
Even for the individuals who have drug insurance coverage, most of them are required to pay a
deductible and/or co-payment for the prescription drugs.
Education
The highest level of education attained by the respondent. Education is defined through a series of
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Y

Y
N

Y

Y

Y

N

N

Working
Status

Insurance

dummy variables (less than high school, high school, some post-secondary, with a degree). Education
has two opposite potential influences on drug utilization: 1) higher education levels are associated with
better health which may have negative influence on drug use. 2) higher education levels are
associated with positive attitude to health care which may have a positive influence on drug use.
Indicator of whether the respondent has held a job (either full time or part time) in the past year. Labour N
force participation has two opposite potential influences on drug utilization: 1) higher time cost and
better health associated with labour force participation may have negative influence on drug use. 2)
higher income and better private drug coverage associated with labour force participation may have a
positive influence on drug use.
Indicator of whether the respondent has insurance that covers all or part of the cost of prescription N
medications (Include any private, government or employer-paid plans). It may positively relate to drug
utilization. This variable is missing in CCHS 2000/01.
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Table-3, Descriptive statistics, Non-senior Population
Non-senior Population
1990 OHS
std
mean
dev.

1996/97 NPHS
std
mean
dev.

2000/01 CCHS
std
mean
dev.

Number of drugs used

1.023

1.825

1.660

1.528

1.836

1.630

Probability of any drug use

0.530

0.757

0.781

0.414

0.805

0.397

Income

16.770 10.721

20.202 14.536

24.482 20.532

Female

0.505

0.500

0.521

0.500

0.501

0.500

Age 15-19

0.106

0.307

0.069

0.254

0.094

0.292

Age 20-24

0.092

0.290

0.086

0.280

0.094

0.292

Age 25-29

0.114

0.318

0.106

0.307

0.092

0.290

Age 30-34

0.122

0.328

0.134

0.340

0.102

0.303

Age 35-39

0.118

0.323

0.137

0.344

0.128

0.334

Age 40-44

0.108

0.310

0.109

0.312

0.119

0.324

Age 45-49

0.087

0.282

0.093

0.290

0.108

0.310

Age 50-54

0.072

0.259

0.085

0.279

0.090

0.286

Age 55-59

0.071

0.257

0.072

0.258

0.067

0.250

Age 60-64

0.066

0.249

0.069

0.253

0.054

0.226

With 1 chronic condition

0.308

0.462

0.270

0.444

0.276

0.447

With 2 chronic conditions

0.176

0.381

0.145

0.352

0.161

0.368

With 3 chronic conditions

0.088

0.283

0.073

0.261

0.082

0.275

With 4+ chronic conditions

0.075

0.263

0.073

0.260

0.081

0.273

Illness/injury in past 2 weeks

0.124

0.330

0.119

0.324

0.094

0.292

Self-assessed health-very good

0.303

0.460

0.403

0.491

0.385

0.487

Self-assessed health-good

0.214

0.410

0.238

0.426

0.235

0.424

Self-assessed health-fair

0.053

0.225

0.067

0.249

0.064

0.246

Self-assessed health-poor

0.013

0.115

0.024

0.153

0.026

0.158

Education-high school

0.242

0.429

0.181

0.385

0.210

0.408

Education-some post secondary

0.237

0.425

0.403

0.491

0.349

0.477

Education-degree

0.109

0.312

0.167

0.373

0.193

0.394

Immigrant

0.190

0.392

0.189

0.392

0.307

0.461

Working

0.634

0.482

0.649

0.477

0.745

0.436

Additional insurance

0.717

0.451

0.680

0.466

---

---
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Table-4, Descriptive statistics, senior Population
Senior Population
1990 OHS
std
mean dev.

1996/97 NPHS 2000/01 CCHS
std
std
mean dev. mean dev.

Number of drugs used

2.585 2.735

2.310 1.797

2.983 2.036

Probability of any drug use

0.868 0.810

0.873 0.333

0.922 0.268

Income

14.935 10.387 18.874 11.879 21.950 18.008

Female

0.561 0.496

0.598 0.490

0.561 0.496

Age 65-69

0.377 0.485

0.313 0.464

0.310 0.462

Age 70-74

0.259 0.438

0.293 0.455

0.282 0.450

Age 75-79

0.205 0.404

0.196 0.397

0.213 0.409

1 chronic conditions

0.229 0.420

0.216 0.412

0.176 0.381

2 chronic conditions

0.222 0.416

0.212 0.409

0.204 0.403

3 chronic conditions

0.172 0.378

0.156 0.363

0.183 0.387

4+ chronic conditions
Illness/injury in past 2
weeks
Self-assessed health-very
good

0.247 0.432

0.245 0.430

0.315 0.465

0.153 0.360

0.139 0.346

0.072 0.259

0.242 0.429

0.301 0.459

0.241 0.427

Self-assessed health-good

0.276 0.447

0.333 0.471

0.320 0.466

Self-assessed health-fair

0.153 0.360

0.173 0.378

0.217 0.412

Self-assessed health-poor

0.031 0.173

0.059 0.236

0.100 0.300

Education-high school
Education-some post
secondary
Education-have a
degree/bachelor, Master,
PhD

0.179 0.384

0.195 0.396

0.199 0.399

0.135 0.342

0.259 0.438

0.249 0.433

0.053 0.223

0.088 0.284

0.103 0.304

Immigrant

0.272 0.445

0.275 0.446

0.405 0.491

Working

0.068 0.252

0.051 0.219

0.094 0.292

Additional insurance

0.689 0.463

0.600 0.490

---
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Table 5, Concentration index for observed drug utilization

1990 OHS

1996-97 NPHS

2000-01 CCHS

Concentration
Index

t-statistics

Concentration
Index

t-statistics

Concentration
Index

t-statistics

Senior

-0.0657

-5.1328

-0.0094

-1.1899

-0.0229

-2.8272

Nonsenior

-0.0210

-2.9577

0.0108

2.5714

0.0118

3.0256
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Table-6, Horizontal Inequity Index
1990 OHS

1996-97 NPHS

2000-01 CCHS

Horizontal
Horizontal
Horizontal
t-statistics
t-statistics
t-statistics
Inequity Index
Inequity Index
Inequity Index
Senior
NonProbability of drug use senior
Senior
Number of drug use
conditional on positive Nonuse
senior
Senior
Total number of drug
use

Nonsenior

-0.0042

-0.7500

0.0019

0.6129

0.0061

3.5882

0.0114

2.3750

0.0174

10.8750

0.0187

18.7000

-0.0200

-1.6667

0.0216

3.7241

0.0178

4.0455

-0.0466

-1.9256

0.0371

9.5128

0.0321

11.4643

-0.0112

-1.0667

0.0230

4.8936

0.0208

5.4737

-0.0074

-1.1935

0.0317

11.3214

0.0282

13.4286
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Table-7, Contribution to the income-related inequality in the number of drug use

Income
Female
Age

Senior
Non-senior
Contribution to Overall CI
Contribution to Overall CI
1990
1996/97 2000/01 1990
1996/97 2000/01
-0.0083 0.0133 0.0026 -0.0023 0.0063 0.0102
0.0003 -0.0005 -0.0015 -0.0030 -0.0040 -0.0051
-0.0021

0.0001

0.0005

0.0176 -0.0012 0.0024

-0.0114

-0.0194

0.0045 -0.0010 0.0003

-0.0021

-0.0008

0.0002 -0.0020 -0.0018

-0.0168

-0.0216

-0.0187 -0.0137 -0.0136

0.0005

-0.0002

0.0025

-0.0053 0.0062 0.0054

0.0019
-0.0020

0.0010
-0.0008

0.0037
0.0007

0.0002 0.0028 0.0082
-0.0075 -0.0008 0.0009

-0.0005
-0.0181
-0.0657

0.0029
0.0052
-0.0094

--0.0105
-0.0229

0.0052 0.0077 ---0.0119 0.0080 0.0048
-0.0210 0.0108 0.0118

Chronic
Conditions
-0.0111
Illness and injury
in past 2 weeks -0.0007
Self-assessed
Health Status
-0.0257
Education
Immigration
Status
Working Status
Additional
Insurance
Error
CI
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Figures

Number of drug use

Figure 1. Number of drugs used,by income quartile
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Number of drug use

Figure 2. Number of drugs used for those who have
consumed drugs, by income quartile
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Figure 3. Contribution to concentration indices
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